ClinicalTrials.gg
CompletedNCT01750931BA/BE: 250/12Updated Jul 17, 2017Results posted

This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.

An interventional study of Meloxicam GSK 15mg and Mobic 15mg in Arthritis, Rheumatoid, sponsored by GlaxoSmithKline. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-17.

Sponsored by GlaxoSmithKline · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · GlaxoSmithKline.

Enrollment
29th of 40
28 · median 52
Started
2013
with 1 other
No phase
Only one
of the 44
Registered
28th of 44
by date

Among the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, this one is the 29th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2013, is the only one with no phase, and was the 28th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, or all of them as a file.
02

Study summary

It is a randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study of Meloxicam GSK 15 mg tablets manufactured by Savipharm J.S.Cc, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co. KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy, adult, human male subjects under fed condition. It is a pivotal study to demonstrate the bioequivalence of Meloxicam GSK 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition.

This study will enroll 28 healthy adult human male subjects

Read the detailed description

The objectives of this study are to:

To demonstrate the bioequivalence of Meloxicam GSK 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition To monitor the safety of the study subjects. Study design: A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition. It is a pivotal study Sample size estimation: Based on the literature available [Public assesment report Scientific Discussion Meloxicam "Arrow" Tablets 7.5 and 15 mg Meloxicam, DK/H/0905/001-002/MR] sample size of 28 subjects will be enough to meet the study objective. And 28 healthy adult human male subjects will be enrolled.

Screening procedures:

Demographic data, medical and medication histories, complete physical examination, height, weight and BMI as well as 12 lead ECG, chest X-ray [PA view], vital signs [blood pressure, pulse rate, respiratory rate and oral temperature], hematology, biochemistry, HIV1\& 2, Hepatitis B and C, RPR test for Syphilis and urine analysis will be done at screening.

Urine drug screen, Liver chemistry test and Breath alcohol test to be done prior to each check-in.

Breath alcohol test to be done prior to each ambulatory visit blood collection. Housing: The study subjects will be housed at least 11 h prior to drug administration until after the 24 h blood sampling in each study period. The housing will be followed by three ambulatory visits [48, 72 and 96 hr post dose] during each period.

Study Meals Supervised fast for at least 10 h before dosing day breakfast will be maintained in each period. High calorie high fat breakfast will be served to subjects to start to consum 30 minutes before the scheduled dosing time. After dosing lunch, snacks and dinner will be served at 5, 8 and 12 h respectively. Meal plans will be identical for both the study periods.

Water will be permitted ad libitum except for 1 h before and until 1 h after post-dose.

Drug Administration:

As per the randomization schedule, one tablet of either test or reference product will be orally administered to each subject in each period in sitting posture, at 30 minutes after start of consuming served high calorie high fat breakfast on an overnight fast of at least 10 h. The investigational products will be administered with 240 ± 2 mL of water.

Subjects will be instructed not to chew or crush the tablet but should be swallowed. Compliance for dosing will be assessed by identification of subjects with subject ID card, identification of label on investigational product to confirm correct allocation of treatment and checking the oral cavity immediately after dosing.

Restrictions Subjects will remain in upright position [sitting or ambulatory] for two hours after dosing in each period except when clinically indicated to change the posture. The subjects will fast for at least 10 h prior to dosing day breakfast and 5 h post-dose. Water will be permitted ad libitum except for 1 h before and until 1 h after post dose.

Blood sampling:

In each period of the study, 26 blood samples of 6 mL each will be collected in K2EDTA vacutainers via an indwelling catheter placed in one of the forearm veins. Heparin-lock technique will be used to prevent clotting of blood in the indwelling catheter. Before each in-house blood sample is drawn through catheter, 0.5 mL of blood will be discarded so as to purge the heparin containing blood sample in the catheter. Blood can also be collected by direct venipuncture in case of cannula blockage, during ambulatory visits or for any other practical reasons. The two pre-dose blood samples will be collected within a period of 1 h before the drug administration. The post-dose blood samples will be collected at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 h. The 48.0, 72.0 and 96.0 h post dose blood samples will be collected during ambulatory visits by direct venipuncture. Immediately after collection of blood, the sample will be kept in ice bath. After collecting the blood samples from all the subjects at each sampling time point, samples will be centrifuged at 4oC with 3500 rpm for 10 minutes. The plasma samples will be separated in duplicate and stored in pre-labeled polypropylene tubes at -70 ± 10°C or colder pending assay. The time interval between sample collection and the start of centrifugation should not exceed more than 45 minutes.

The total volume of blood drawn including the volume necessary for the laboratory tests, PK sample analysis and the volume of blood discarded before each in house blood draw will be about 360 mL per subject for the entire study.

Washout Period: Washout period will be of at least 14 days, but not exceeding 21 days between two dosing days.

Pharmacokinetic Parameter: Cmax, Tmax, AUC0-t, AUC0-∞, AUC%_Extrap, Kel and t1/2 Analytical Methods: Meloxicam in plasma will be estimated using validated LC-MS/MS method.

Statistical Methods: Statistical analyses will be done using SAS® version 9.2 or higher. Analysis of variance [ANOVA] for log-transformed pharmacokinetic parameters [Cmax, AUC0-t and AUC0-∞] and two one-sided tests [Schuirmann] for bioequivalence will be performed. Power, ratio and 90% confidence interval for log-transformed pharmacokinetic parameters - Cmax, AUC0-t and AUC0-∞ will be calculated.

Standards for Bioequivalence: The calculated 90% Confidence Interval for the test to reference ratio of Meloxicam should fall within the range of 80%-125% for log transformed Cmax, AUC0-t and AUC0-∞ for the conclusion of bioequivalence.

Adverse Events The investigator or site staff is responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE.

AEs will be collected from the start of Study Treatment and until the follow-up contact. Medical occurrences that begin prior to the start of study treatment but after obtaining informed consent may be recorded on the Medical History/Current Medical Conditions CRF.

SAEs will be collected over the same time period as stated above for AEs. However, any SAEs assessed as related to study participation (e.g. study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant medication will be recorded from the time a subject consents to participate in the study up to and including any follow-up contact. All SAEs will be recorded and reported to the sponsor within 24 hours.

Investigators are not obligated to actively seek AEs or SAEs in former study participants. However, if the investigator learns of any SAE, including a death, at any time after a subject has been discharged from the study, and he considers the event reasonably related to the study treatment or study participation, the investigator would promptly notify the sponsor.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • BE study of Meloxicam GSK 15mg
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male human subjects within the age range of 18 to 45 years inclusive.
  • Heght not less than 50 kg.
  • Normal [18.5 to 24.99 kg/m2 inclusive].
  • Willingness and capability to provide written to participate in the study.
  • Free of significant diseases or abnormal findings based on medical history, physical examination, laboratory evaluations, 12-lead , Chest X-ray [PA view].
  • Absence of disease markers of 1 and 2, and C and Syphilis.
  • , ALT, alkaline phosphatase and ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • ECG normal for morphology and measurements. or QTcF \< 450 msec or QTc \< 480 msec in subjects with Bundle Branch Block, based on an average from three ECGs obtained over a brief recording period.
  • Male subjects with female partners of must agree to use one of the methods listed below. This criterion must be followed from the time of the first dose of study medication until one week of last dose administration.
  • Condom plus partner use of a highly effective contraceptive such as occlusive cap (diaphragm or cervical/vault cap) plus spermicidal agent (foam/gel/film/cream/suppository), oral contraceptive, injectable progesterone, implant of etonogestrel or levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, or intrauterine device.

OR

  • Abstinence, defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

Exclusion criteria

Exclusion Criteria:

  • History or presence of significant: Cardiovascular, pulmonary, hepatic, renal, hematological, gastro-intestinal, endocrine, immunologic, dermatologic, neurological, psychiatric disease.
  • History or presence of significant:
  • Alcohol dependence or alcohol abuse during past one year.
  • Drug abuse [Marijuana [THC], Cocaine, Morphine, Benzodiazepines, Barbiturates and Amphetamine] for the last 6 months.
  • Smoking of more than 5 cigarettes per day or consumption of other forms of tobacco containing products.
  • Asthma, urticaria or other allergic type reactions after taking aspirin or any other drug.
  • Ulceration or history of gastric and / or duodenal ulcer.
  • Jaundice in the past 6 months.
  • Bleeding disorder.
  • Allergy to the test drug or any drug chemically similar to the drug or to the of the products under investigation.
  • Donation of 500 mL or more blood within 8 weeks prior to receiving the first dose of study drug.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Any difficulty in accessibility of forearm veins for cannulation or blood sampling.
  • Refusal to consume high calorie high fat breakfast 30 minutes before scheduled dosing time and abstain from food for at least 5 h post dose in each period.
  • Refusal to abstain from fluid for at least 1 h prior to and 1 h post each dose.
  • Positive breath alcohol test result found on the day of check-in.
  • Positive urine test result for drug of abuse found on the day of check-in.
  • History of difficulty in swallowing tablet.
  • Use of any concomitant medication [including over-the-counter products, vitamins etc.] for 14 days preceding the study drug administration.
  • Use of drugs which induce or inhibit metabolizing enzymes within 30 days prior to receiving the first dose of study medication.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    Meloxicam GSK 15mg

    A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition

    Drug: Meloxicam GSK 15mg · Drug: Mobic 15mg

  • Other
    Mobic 15mg

    A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition

    Drug: Meloxicam GSK 15mg · Drug: Mobic 15mg

Interventions

  • DrugMeloxicam GSK 15mg

    To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \&amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition

  • To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition

06

What researchers measure

Primary outcomes

  1. Maximum Drug Concentration During the Selected Dosing Interval (Cmax) After a Single Dose

    Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. The Cmax was taken directly from the plasma concentration-time profile of individual participants

    Time frame: Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period

  2. Time to Maximum Concentration (T-max)

    Plasma samples for PK analysis were drawn at indicated time points of each treatment period. The Tmax was taken directly from the plasma concentration-time profile of individual participants. Plasma samples for PK analysis were drawn at indicated time points.

    Time frame: Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period

  3. The Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose

    Plasma samples for PK analysis were drawn at indicated time points of each treatment period. AUC(0-t) was area under the plasma concentration-time curve from time of administration until the time of last quantifiable concentration. The area under the plasma concentration-time curve (AUC0-infinity), was estimated by linear trapezoidal rule and was sum of the AUC0-t and extrapolated to infinity by dividing the estimated last measurable plasma concentration by elimination rate constant lambda z. Where lambda z is the terminal phase rate constant estimated by linear regression analysis of the log transformed concentration-time data after each single dose. The AUC0-infinity was the sum of the estimated and extrapolated parts.

    Time frame: Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period

  4. The Percentage of Area Under Curve Extrapolated to Arrive at AUC0-infinity (AUCpercentage [%]_Extrap [Residual Area]) After a Single Dose

    Plasma samples for PK analysis were drawn at indicated time points of each treatment period. The percentage of area under curve extrapolated to arrive at AUC0-infinity (AUC%_Extrap \[residual area\]) was determined by AUC0-infinity minus AUC0-t divided by AUC0-infinity multiplied by 100.

    Time frame: Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period

  5. Elimination Rate Constant (Kel) After a Single Dose

    Plasma samples for PK analysis were drawn at indicated time points of each treatment period. The apparent first-order elimination or terminal rate constant was calculated from a semilogarithmic plot of the plasma concentration versus time. The parameter was calculated by linear least-square regression analysis using the last three (or more) non-zero plasma concentrations.

    Time frame: Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period

  6. Elimination Half Life (T-half) After a Single Dose

    The T-half was calculated using the following formula by dividing 0.693 (natural logarithm of 2) with lambda z, where lambda z is the terminal phase rate constant estimated by linear regression analysis of the log transformed concentration-time data after each single dose.

    Time frame: Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period

Secondary outcomes

  1. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, is medically important event or reaction, is associated with liver injury Alanine amino transferase (more than equal to \[\>=\] 3 fold upper normal of limit \[ULN\]) or total bilirubin (\>=2 fold ULN) or international normalization ratio more than 1.5. Refer to the general AE/SAE module for a list of AEs and SAEs.

    Time frame: Up to 20 days

07

Results

Posted Jul 17, 2017

Participant flow

Total 28 participants were enrolled from September-2013 to October-2013. At each study period participants received test (GlaxoSmithKline \[GSK\]-meloxicam 15 milligram \[mg\] tablet) and reference (Mobic®-meloxicam 15 mg tablet) products. Mobic is registered product of Boehringer Ingelheim Pharma GmbH and Company, Germany.

Period 1
Participant flow — Period 1
MilestoneGSK-meloxicam Then Mobic-meloxicamMobic-meloxicam Then GSK-meloxicam
Started1414
Completed1414
Not completed00
Wash Out
Participant flow — Wash Out
MilestoneGSK-meloxicam Then Mobic-meloxicamMobic-meloxicam Then GSK-meloxicam
Started1414
Completed1414
Not completed00
Period 2
Participant flow — Period 2
MilestoneGSK-meloxicam Then Mobic-meloxicamMobic-meloxicam Then GSK-meloxicam
Started1414
Completed1414
Not completed00

Outcome measures

PrimaryMaximum Drug Concentration During the Selected Dosing Interval (Cmax) After a Single Dose

Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. The Cmax was taken directly from the plasma concentration-time profile of individual participants

Time frame:
Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period
Reported as:
Geometric mean · Nanogram per milliliter
Maximum Drug Concentration During the Selected Dosing Interval (Cmax) After a Single Dose
Nanogram per milliliterGSK-meloxicam 15 mgMobic-meloxicam 15 mg
Maximum Drug Concentration During the Selected Dosing Interval (Cmax) After a Single Dose1889.579 ± 15.311844.423 ± 15.74
Statistical analysis
  • GSK-meloxicam 15 mg vs Mobic-meloxicam 15 mg · ANOVA · p = 0.4396 · Percent ratio: 102.45 · 95% CI 99.40 to 105.59
PrimaryTime to Maximum Concentration (T-max)

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. The Tmax was taken directly from the plasma concentration-time profile of individual participants. Plasma samples for PK analysis were drawn at indicated time points.

Time frame:
Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period
Reported as:
Median · Hour
Time to Maximum Concentration (T-max)
HourGSK-meloxicam 15 mgMobic-meloxicam 15 mg
Time to Maximum Concentration (T-max)5.50 ± 16.05.50 ± 14.7
PrimaryThe Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. AUC(0-t) was area under the plasma concentration-time curve from time of administration until the time of last quantifiable concentration. The area under the plasma concentration-time curve (AUC0-infinity), was estimated by linear trapezoidal rule and was sum of the AUC0-t and extrapolated to infinity by dividing the estimated last measurable plasma concentration by elimination rate constant lambda z. Where lambda z is the terminal phase rate constant estimated by linear regression analysis of the log transformed concentration-time data after each single dose. The AUC0-infinity was the sum of the estimated and extrapolated parts.

Time frame:
Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period
Reported as:
Geometric mean · Nanogram.hour per milliliter
The Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose
Nanogram.hour per milliliterGSK-meloxicam 15 mgMobic-meloxicam 15 mg
AUC(0-t)57499.339 ± 31.0054750.590 ± 33.21
AUC(0-inf)62687.372 ± 44.4961269.334 ± 50.30
Statistical analysis
  • GSK-meloxicam 15 mg vs Mobic-meloxicam 15 mg · ANOVA · p = 0.9712 · Percent ratio: 105.02 · 95% CI 99.69 to 110.63Comparison of AUC0-t between group GSK-meloxicam 15 mg and Mobic-meloxicam 15 mg
  • GSK-meloxicam 15 mg vs Mobic-meloxicam 15 mg · ANOVA · p = 0.9951 · Percent ratio: 102.31 · 95% CI 99.05 to 105.69Comparison of AUC0-infinity between group GSK-meloxicam 15 mg and Mobic-meloxicam 15 mg
PrimaryThe Percentage of Area Under Curve Extrapolated to Arrive at AUC0-infinity (AUCpercentage [%]_Extrap [Residual Area]) After a Single Dose

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. The percentage of area under curve extrapolated to arrive at AUC0-infinity (AUC%_Extrap \[residual area\]) was determined by AUC0-infinity minus AUC0-t divided by AUC0-infinity multiplied by 100.

Time frame:
Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period
Reported as:
Geometric mean · Percentage of AUC Extrapolated
The Percentage of Area Under Curve Extrapolated to Arrive at AUC0-infinity (AUCpercentage [%]_Extrap [Residual Area]) After a Single Dose
Percentage of AUC ExtrapolatedGSK-meloxicam 15 mgMobic-meloxicam 15 mg
The Percentage of Area Under Curve Extrapolated to Arrive at AUC0-infinity (AUCpercentage [%]_Extrap [Residual Area]) After a Single Dose4.32 ± 119.85.02 ± 132.1
PrimaryElimination Rate Constant (Kel) After a Single Dose

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. The apparent first-order elimination or terminal rate constant was calculated from a semilogarithmic plot of the plasma concentration versus time. The parameter was calculated by linear least-square regression analysis using the last three (or more) non-zero plasma concentrations.

Time frame:
Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period
Reported as:
Geometric mean · Per hour
Elimination Rate Constant (Kel) After a Single Dose
Per hourGSK-meloxicam 15 mgMobic-meloxicam 15 mg
Elimination Rate Constant (Kel) After a Single Dose0.032 ± 33.910.030 ± 34.50
PrimaryElimination Half Life (T-half) After a Single Dose

The T-half was calculated using the following formula by dividing 0.693 (natural logarithm of 2) with lambda z, where lambda z is the terminal phase rate constant estimated by linear regression analysis of the log transformed concentration-time data after each single dose.

Time frame:
Pre-dose (two samples collected within a period of 1 hour) and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0 and 96.0 hours post-dose in each treatment period
Reported as:
Median · Per hour
Elimination Half Life (T-half) After a Single Dose
Per hourGSK-meloxicam 15 mgMobic-meloxicam 15 mg
Elimination Half Life (T-half) After a Single Dose21.362 (11.437 to 66.697)22.337 (12.522 to 92.217)
SecondaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, is medically important event or reaction, is associated with liver injury Alanine amino transferase (more than equal to \[\>=\] 3 fold upper normal of limit \[ULN\]) or total bilirubin (\>=2 fold ULN) or international normalization ratio more than 1.5. Refer to the general AE/SAE module for a list of AEs and SAEs.

Time frame:
Up to 20 days
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsGSK-meloxicam 15 mgMobic-meloxicam 15 mg
Any AE01
Any SAE00

Adverse events

Collected over AE and SAE were reported through out the study (up to 20 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK-meloxicam 15 mg0/28 (0%)0/28 (0%)0/28 (0%)
Mobic-meloxicam 15 mg0/28 (0%)0/28 (0%)1/28 (3.6%)
Most frequent other events
Most frequent other events
EventGSK-meloxicam 15 mgMobic-meloxicam 15 mg
HeadacheGeneral disorders0/281/28

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK-meloxicam 15 mg + Mobic-meloxicam 15 mg
Years25.04 ± 4.14
Sex: Female, Male
Sex: Female, Male(Participants)GSK-meloxicam 15 mg + Mobic-meloxicam 15 mg
Female0
Male28
Region of Enrollment
Region of Enrollment(Participants)GSK-meloxicam 15 mg + Mobic-meloxicam 15 mg
India28
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Oct 2013, 0 months.

Results were first posted in Jul 2017, 3 years 9 months after primary completion.

Of 56 industry-sponsored interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 92. This study's 0 months is below that.

Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2012
First posted
Dec 17, 2012
StartActual
Sep 12, 2013
Primary completionActual
Oct 1, 2013
CompletionActual
Oct 1, 2013
Results first posted
Jul 17, 2017
Last update
Jul 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01750931
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 17, 2012
Start date
Sep 12, 2013
Primary completion
Oct 1, 2013
Completion
Oct 1, 2013
Results posted
Jul 17, 2017
Last update
Jul 17, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion